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 CURRENTOPINION Symptom-based patient-reported outcomes
in adults with eosinophilic esophagitis: value
for treatment monitoring and randomized
controlled trial design1528-4050 Copyright  2019 Wolte
opyright © 2019 Wolters a bEkaterina Safroneeva and Alain M. SchoepferPurpose of review
In adults with eosinophilic esophagitis (EoE), a chronic, inflammatory immune-mediated condition of the
esophagus, both inflammation and fibrosis are likely associated with symptom generation. Therefore,
assessing symptom-based patient-reported outcomes (PROs), defined by US Food and Drug Administration
as ‘any report of the status of a patient’s health condition that comes directly from the patients, without
interpretation of the patient’s response by a clinician or anyone else’, is important in the context of trials
and observational studies of emerging therapies.
Recent findings
For purposes of treatment monitoring, lack of symptoms does not predict the absence of biologic
inflammation; hence, endoscopy with esophageal biopsies should be performed to check for residual
inflammation. Lack of inflammation does not predict lack of symptoms, and the presence of subepithelial
fibrosis cannot be excluded. No published instrument currently measures the frequency of dysphagia
described all possible ways, strategies of living with this symptom and various pain types. In randomized
controlled trials, in which symptom response was detected using validated PRO measures, only modest
decreases in symptom scores were observed.
Summary
Accessing full EoE symptom spectrum and optimizing PRO measures remains a challenge that should be
tackled to reliably assess response to existing and emerging therapies.
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Eosinophilic esophagitis (EoE) is a chronic, inflam-
matory immune-mediated condition of the esoph-
agus, which is diagnosed based on the presence of
symptoms of esophageal dysfunction and esoph-
ageal eosinophilia (threshold of > 15 eosinophils
per high-power field) [1]. With current incidence
estimates from 5 to 10 cases per 100 000 and current
prevalence estimates from 0.5 to 1 case per 1000,
EoE is recognized as frequent cause of dysphagia (in
up to 23% of all patients) and food bolus
impactions (in up to 50% of all patients) [1,2].
It has been shown that, in adults with EoE,
duration of untreated inflammation is positively
associated with fibrosis and stricture formation
[3,4
&&
,5].rs Kluwer Health, Inc. All rights rese
Kluwer Health, Inc. UnaSYMPTOM GENERATION IN ADULTS WITH
EOSINOPHILIC ESOPHAGITIS
It is likely that both inflammation and fibrosis are
associated with symptom generation in adults with
EoE. Endoscopic manifestations of fibrosis in EoE
include rings and strictures. In a series of studies
utilizing the functional luminal imaging proberved. www.co-allergy.com
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KEY POINTS
 Both inflammation and fibrosis are likely associated
with symptom generation.
 Symptom-based PRO measures should be used for
treatment monitoring.
 There is disconnect between severity of symptoms and
biologic findings.
 Only modest decreases in dysphagia frequency-based
PRO scores were observed in trials of anti-inflammatory
therapies.
 Accessing full EoE symptom spectrum using PRO
measures remains a challenge.
Genetics and epidemiology
Cop(examines regional variation of cross-sectional area,
from which researchers calculate distensibility
plateau considered to be a proxi for transmural
remodeling/fibrosis), authors demonstrated that
increasing ring grade as assessed by ‘EoE endoscopic
reference score (also stands for exudates, rings,
edema, furrows, and strictures, EREFS)’ grading
and classification system was associated with lower
esophageal distensibility plateau, and that disten-
sibility plateau in patients, who presented with food
impaction, was lower than in patients who did not
[6–8]. Warners et al. [4
&&
] observed an association
between stricture formation and bolus impactions
in 106 patients. In the remaining 124 patients with
bolus impactions, no stricture was observed [4
&&
]. In
International Eosinophilic Esophagitis Activity
Index (EEsAI), patient global assessment of symp-
tom severity was positively associated not only with
increasing ring/stricture severity but also with
increased severity of exudates assessed by EREFS
[9]. Given that distensibility was not measured in
Dutsch [4
&&
] and Swiss [9] studies, it is impossible to
exclude the role of underlying fibrosis in the absence
of obvious strictures in symptom generation. How-
ever, it is likely that extreme forms of inflammation
are contributing to overall symptom severity. How
exactly inflammation contributes to symptom gen-
eration remains to be elucidated. For example, no
association between distensibility and either esoph-
ageal eosinophilia or exudates were observed [6,7].
With more than 100 patients enrolled (only five
individuals with severe exudates), a jury is still
out on whether inflammation decreases the cross-
sectional area of the esophagus to an extent that
would cause symptoms. Recently, a study describing
a case series of eight patients put forward another
mechanism through which inflammation may cause
symptoms. Upon injection of the solution contain-
ing trigger food antigen (so-called ‘Esophageal Prick2 www.co-allergy.com
yright © 2019 Wolters Kluwer Health, Inc. UnauthTest’), authors observed almost immediate complete
luminal obstruction that resolved after 3–10 min. In
two patients, delayed responses were also observed
upon second endoscopy. For the moment being, it is
too early to say whether these spastic episodes might
be a cause of bolus impactions and potentially other
symptoms [10
&
].PATIENTS-REPORTED OUTCOME
MEASURES IN EOSINOPHILIC
ESOPHAGITIS
Given that the pathophysiologic hallmarks of EoE
likely influence symptom severity, assessing symp-
toms appears to be paramount in daily clinical prac-
tice, observational studies and randomized clinical
trials (RCTs).Although bolus impactionsanddyspha-
gia are well-documented symptoms of EoE, these and
other less well-known EoE symptoms are mostly
described from the perspective of a medical provider.
However, in order to arrive at the patient-reported
outcome (PRO), defined by US Food and Drug
Administration (FDA) as ‘any report of the status of
a patient’s health condition that comes directly from
the patients, without interpretation of the patient’s
response by a clinician or anyone else’, it is important
to explore the way patients describe symptoms and
other aspects of health [11]. In this review, we will
focus on symptom-based PRO measures.SYMPTOMS OF EOSINOPHILIC
ESOPHAGITIS AS PATIENTS DESCRIBE
THEM
Large qualitative studies exploring the full symptom
spectrum in adults with EoE are scare; however,
these are required by US FDA to inform the content
of the PRO measure [11]. As a part of the EEsAI PRO
study, the thematic content analyses of the patient
interviews’ (n¼24) and survey’ (n¼135) transcripts
were carried out [9]. As a part of development of
Dysphagia Symptom Questionnaire (DSQ), 20
patients were interviewed to specifically describe
their dysphagia-related concerns, and thematic
analysis was carried out [12].Dysphagia
Dysphagia is the most frequent symptom in adults
with EoE. Three dysphagia-related themes were
identified in EEsAI PRO study: descriptions and
characteristics (frequency and location) of dyspha-
gia; foods, pills and beverages causing dysphagia;
and behavioral adaptations to living with dysphagia
(two subthemes, including strategies for avoiding
and dealing with impactions) (Fig. 1) [9]. DuringVolume 18  Number 00  Month 2018
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FIGURE 1. Dysphagia from patients’ perspective.
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DSQ development, descriptions of dysphagia and
strategies dealing with dysphagia were explored
[11]. Conceptually, both Swiss and US-based
patients think of dysphagia in variety of ways, which
included trouble swallowing (only detected using
EEsAI PRO qualitative work), delayed passage of
food, impactions (or food being stuck) and tighten-
ing of the esophagus [9,11]. At present, EEsAI PRO
instrument assessed the frequency of dysphagia
described as trouble swallowing, whereas furthest
validated measure of dysphagia frequency, DSQ,
assessed the frequency dysphagia described in two
ways, namely food impactions (or food being stuck)
and delayed food passage. Although neither instru-
ment uses ‘tightening of the esophagus’ to describe
dysphagia, patients’ quotes supporting the use of
this term have been demonstrated in articles
describing the development of both instruments
[9,12]. Although sensation of esophageal tightening
might be important in the context of the immedi-
ate/delayed reactions to EoE food triggers [10
&
],
patients used this description in the context of
eating relatively dense foods, like meat. Strategies
of avoiding and dealing with dysphagia episodes
have been described during EEsAI PRO and DSQ
development. Strategies of avoiding dysphagia epi-
sodes include avoiding certain mostly dense or very
dry foods, modifying certain foods, trying to chew
food more carefully and drinking copious amounts1528-4050 Copyright  2019 Wolters Kluwer Health, Inc. All rights rese
opyright © 2019 Wolters Kluwer Health, Inc. Unaof liquids [9]. As for strategies dealing with dyspha-
gia episodes, simply waiting, drinking liquids
(which may or may not help the cause), trying to
get the food back out (mostly described by Swiss
German patients as vomiting and regurgitation and
English-speaking US patients as vomiting, choking,
coughing and gagging of the foods) and seeking
medical attention to dislodge impacted food have
been commonly described by the patients [9,12].
Adult EoE patients develop many strategies to deal
with dysphagia episodes (including exercise and
various relaxation techniques), and only the most
common ones should be captured by dysphagia-
assessing PRO instruments. Although both English
and German belong to the same group of West
Germanic languages, the way patients describe try-
ing to get the food back out appears to be different,
pointing to the importance of cross-cultural adap-
tations of the dysphagia-assessing PRO instruments.
EEsAI PRO and DSQ instrument developers pro-
ceeded to include strategies of avoiding dysphagia
(eating slowly, modifying and avoiding foods) and
strategies of dealing with dysphagia (waiting, drink-
ing liquids, vomiting, gagging, coughing and seek-
ing medical attention to dislodge the impacted
food) into their respective instruments [9,12]. In
summary, PRO instruments published to date use
different descriptions of dysphagia for assessing fre-
quency of this symptom and examine differentrved. www.co-allergy.com 3
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Genetics and epidemiology
Copstrategies of living with dysphagia. Future studies
are needed to find out whether items containing all
possible descriptions of dysphagia would be more
sensitive in identifying patients with this symptom
compared to items currently used in EEsAI PRO and
DSQ, respectively. Similarly, the studies with head-
to-head comparisons of the extent to which various
strategies of living with dysphagia contribute to
overall patient symptom severity should be
carried out.Others
Although developers of DSQ were mostly interested
in dysphagia, EEsAI PRO developers identified other
important themes, including swallowing-associated
and nonswallowing-associated pain. In nearly 40%
of all patients, only food ingestion-associated
themes emerged. In addition to already described
dysphagia, the presence of pain when swallowing
contributed in an important way to variation in
patient global assessment of symptom severity
and was included into the EEsAI PRO instrument.
Although swallowing-associated pain and dyspha-
gia are important to a large proportion of patients,
other concerns relevant to patients, such as non-
swallowing-associated symptoms, receive little
attention [13] Evaluated as a part of the EEsAI
PRO study, the presence of nonswallowing-associ-
ated pain was not associated with variation in
patient global assessment of symptom severity. It
remains to be determined whether pain intensity
assessed using visual analogue scale were to perform
better in explaining variation in patient global
assessment of symptom severity. To simplify the
symptom-based PRO instruments and diminish
the burden on patients, as they complete these
instruments on daily bases during RCT, the con-
cerns falling outside of dysphagia assessment are
often left behind. Other reasons why these concerns
are overlooked include that they are less frequent
than dysphagia, and that relatively small sample
sizes of patients are often used to develop symp-
tom-based PRO instruments in adults with EoE.
In summary, accessing a full spectrum of EoE-
associated symptoms using PRO measures remains a
challenge, and no published instrument currently
measures the frequency of dysphagia described all
possible ways, strategies of living with this symptom
and various types of pain. Moving forward, existing
and new instruments will continue to be validated
and compared to arrive at optimal assessment of
dysphagia and other EoE symptoms in adults. It may
very well be that we will not need to describe dys-
phagia in four ways to assess its frequency, but we
need the studies to show that.4 www.co-allergy.com
yright © 2019 Wolters Kluwer Health, Inc. UnauthVALUE OF SYMPTOMS FOR TREATMENT
MONITORING
In adults with EoE, the relationship between symp-
toms, whether assessed by a validated PRO tool or
not, and biologic findings continues to be a subject
of much debate. The conflicting reports from rela-
tively small RCT (old and new) have hinted that the
relationship between symptoms and biologic find-
ings, such as esophageal eosinophilia, may not be
linear [9]. The data from relatively large (n¼269) for
a rare disease observational, cross-sectional EEsAI
study have demonstrated that EEsAI PRO score of
20 identified patients in endoscopic remission with
65.1% accuracy and histologic remission with
62.1% accuracy, whereas EEsAI PRO score of 15
identified patients with both types of remission with
67.7% accuracy [14]. Reed et al. [15] approached a
similar question from a different stand-point by
examining the response to treatment in 62 conse-
cutive patients. In patients who achieved histologic
remission of less than 15 eosinophils per high-power
field (eos/hpf), 70% had an endoscopic response,
46% had a symptomatic response and 34% had
both. In patients who achieved histologic remission
of 0 eos/hpf posttreatment, 74% had an endoscopic
response, 43% had symptomatic response and 38%
had both. As such, for the purposes of treatment
monitoring, lack of symptoms, assessed by EEsAI
PRO (7-day recall), does not predict the absence of
biologic inflammation; hence, endoscopy with
esophageal biopsies should be performed to find
out whether residual inflammation is controlled
by a given therapy. Naturally, these observations
need to be confirmed using data from other large
studies. In addition, lack of inflammation does not
predict lack of symptoms, and the presence of sub-
epithelial fibrosis cannot be excluded. When disten-
sibility assessment becomes more main stream, this
relationship between symptoms, inflammation and
fibrosis needs to be re-examined.SYMPTOM-BASED PATIENT-REPORTED
OUTCOMES INSTRUMENTS IN
RANDOMIZED CONTROLLED TRIALS
Although many investigator-initiated studies to
assess efficacy of mostly corticosteroid therapies
have been carried over the years, none of these
studies used validated symptom-based PRO mea-
sures, and, hence, will not be discussed here. To
date, the results of four phase II and phase III RCTs,
in which symptom response was assessed either
using DSQ (and similar instruments assessing the
frequency of dysphagia) or EEsAI PRO, have been
published in a form of full articles or abstracts
presented during international meetings. It is alsoVolume 18  Number 00  Month 2018
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worth keeping in mind that certain phase II studies
were not powered to detect symptom response.
Daily assessment of symptoms in adults with EoE
is one of the primary tenants of US FDA PRO Guid-
ance for the Industry, so electronic DSQ was admin-
istered daily, whereas 7-day recall period EEsAI PRO
was administered in either article or electronic form
[11]. Phase II and III RCTs to assess the efficacy and
safety of various anti-inflammatory therapies have
been relatively small in comparison to those carried
out in other chronic conditions.
Dellon et al. [16
&&
] reported the results of the
phase II study on the efficacy and safety of 12-week
4 mg budesonide suspension in 93 individuals with
EoE (age ranged from 11 to 40 years of age). This
budesonide formulation proved efficacious in
reducing esophageal eosinophilia (mean decrease
of 117 eos/hpf in drug treated vs. decrease of
17 eos/hpf in placebo-treated group, P< .001) and
DSQ score [mean decrease (standard deviation) of
14.313.0 points in drug-treated group vs. decrease
of 7.510.7 points in placebo-treated group,
P¼0.0096]. The difference of less than 7 points
separated drug-treated patients from those treated
with placebo (DSQ ranges 0–84). In phase III study
of budesonide orodispersible tablet, 88 adults with
EoE were treated for 6 weeks with either 2 mg bude-
sonide orodispersible tablets (n¼59) or placebo
(n¼29) [17]. Once again, budesonide has proven
to be efficacious in reducing esophageal eosino-
philia (mean change of 226 eosinophils per
mm2 in drug treated vs. 4 eosinophils per mm2,
P<0.0001) and EEsAI PRO score (50.8% of patients
achieved clinical remission defined as EEsAI
PRO20 in drug-treated group vs. 6.9% of patients
in placebo-treated group, P<0.0001).
Efficacy and safety of RPC4046, anti-interleukin
(IL)-13 antibody, was evaluated in a phase II trial in
adults with EoE [18
&
]. Ninety-nine adults were ran-
domized into one of three groups given RPC4046
(180 or 360 mg) or placebo once weekly for 16 weeks.
At week 16, mean decrease of 90 or more eos/hpf in
drug-treated groups was observed compared to an
increase in 4.4 eos/hpf in a placebo group. At week
16, mean decrease ( standard deviation) in the
dysphagia symptom diary (similar to DSQ instru-
ment assessing dysphagia frequency) score was
greater in the 360 mg RPC4046 group compared
with the placebo group (13.315.3 in drug-treated
group vs. 6.4115.40 in a placebo-treated group,
P¼0.0733). A trend for difference between mean
change in EEsAI PRO in RPC4046 360 mg vs. placebo
(difference of approximately 5–6 points between
two groups, EEsAI PRO ranges 0–100) was observed.
Finally, in a phase II study, the efficacy and safety of
dupilumab, anti-IL-4Ra monoclonal antibody, was1528-4050 Copyright  2019 Wolters Kluwer Health, Inc. All rights rese
opyright © 2019 Wolters Kluwer Health, Inc. Unaevaluated in adults with EoE [19]. At week 12, a
mean decrease of 94 eos/hpf in drug-treated groups
was observed compared to decrease of 7 eos/hpf in
the placebo group. At week 10, mean decrease in the
EEsAI PRO score was greater in the dupilumab group
compared to the placebo group (34.6 in drug-treated
group vs. 11.3 in a placebo-treated group, P¼0.085).
At times, it is difficult to compare these studies.
Relatively severe patients were enrolled into all
above-mentioned studies, and only modest (signifi-
cant or trends) decreases in symptom scores were
observed. Why this was the case remains to be
determined. It could be that no instruments used
all-encompassing dysphagia descriptions. It is also
likely that, as patients start feeling better, they could
be changing from softer to denser foods, while
having the same dysphagia frequency. Whether
patients explore denser food consistencies as these
short-term studies progress has not been assessed.
However, the data of the open-label extension (OLE)
part of the RPC4046 study showed that EoE patients’
dysphagia score continues to improve (the propor-
tion of patients achieving symptomatic remission
defined as EEsAI PRO score 20 was 24.4% at OLE
baseline, and 58.2% at week 52 with the caveat that
there was no placebo arm) [20]. As phase II studies
pave the way for large phase III RCT, these hypoth-
eses will need to be explored.CONCLUSION
EoE researchers, patients and other stakeholders will
arrive at a core outcome set, including symptoms-
based PRO, that will be used in RCT, observational
studies and clinical practice [21]. However, assessing
only dysphagia frequency in all types of studies
might be too simplistic of an approach. As symp-
tom-based and other PRO instruments get incorpo-
rated into telemedicine and e-health applications,
we might make a distinction between daily dyspha-
gia frequency assessment in RCT and more integra-
tive approach toward symptom assessment during
follow-up.
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